News and updates
EuroBloodNet aims for better care for patients with rare blood disorders
Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States. At the 3rd conference on European Reference Networks in Lithuania, EuroBloodNet was officially awarded as one of the recently approved ERNs.
Impact of new technologies on diagnosis and treatment of anemias highlighted in ...
Hematologists from 18 countries and 4 continents learned more about the new techniques for diagnosis and treatment of anemias during the EHA-SWG Scientific Meeting on Anemias on February 2-4, 2017...
EHA in the BioMed Alliance: joining forces for biomedical research
EHA is an active member of the Alliance for Biomedical Research in Europe (BioMed Alliance), in which Europe’s leading medical societies have joined forces to represent the interests of over 400,000 researchers and health professionals.
HARMONY: Better care of patients with hematologic malignancies kicked off!
“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient...
EHA’s advocacy for hematology continues
EHA is entering the next phase of its Hematology Awareness Campaign this fall. Face-to-face meetings will be conducted with EU institutions and other relevant stakeholders in Brussels, to raise awareness in hematology, increase the visibility of EHA, advocate key EHA positions, contribute to important policy debates and build relationships and alliances.
Young researchers to benefit from EHA training and mentoring
Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.
EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders i...
Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
European Reference Networks, a unique opportunity to take collaboration and pati...
On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).
SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates am...
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Killer antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the...
The Clot Thickens
Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).
Genome sequencing of thousands of patients with rare blood disorders
Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot.
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma ...
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic...
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.